Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient
Nivolumab, an anti-PD-1 check point inhibitor, is an immunotherapeutic agent, representing a major step in the treatment of melanoma. However, its use is associated with severe toxicities. Among them, gastrointestinal (GI) disorders from the lower GI tract have been widely reported. On the contrary,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/12/11/2864 |
| _version_ | 1797465606127091712 |
|---|---|
| author | George Samonis Aikaterini Bousmpoukea Aristea Molfeta Antonios D. Kalkinis Kalliopi Petraki Christos Koutserimpas Dimitrios Bafaloukos |
| author_facet | George Samonis Aikaterini Bousmpoukea Aristea Molfeta Antonios D. Kalkinis Kalliopi Petraki Christos Koutserimpas Dimitrios Bafaloukos |
| author_sort | George Samonis |
| collection | DOAJ |
| description | Nivolumab, an anti-PD-1 check point inhibitor, is an immunotherapeutic agent, representing a major step in the treatment of melanoma. However, its use is associated with severe toxicities. Among them, gastrointestinal (GI) disorders from the lower GI tract have been widely reported. On the contrary, disorders from the upper GI tract are rare. Such a case of delayed nivolumab induced severe gastritis in a 53-year-old Caucasian female patient suffering metastatic melanoma is described. The patient’s symptoms from the upper GI tract began 4 months after nivolumab treatment initiation. The diagnosis was based on imaging, including PET/CT, endoscopical and pathological findings. The side effect was successfully treated with prolonged administration of proton pump inhibitors and corticosteroids. There are only a few cases of immune check point inhibitors (ICPis) induced upper GI tract disorders, while it seems that the symptoms from nivolumab induced upper GI tract damages appear later than those reported in the lower part. Nivolumab, among other side effects, may cause severe gastritis. Hence, this pathological entity should be included in the list of this drug’s side effects. |
| first_indexed | 2024-03-09T18:23:53Z |
| format | Article |
| id | doaj.art-d99b0a5291254e50a56fa7e42ae38561 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-09T18:23:53Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-d99b0a5291254e50a56fa7e42ae385612023-11-24T08:05:29ZengMDPI AGDiagnostics2075-44182022-11-011211286410.3390/diagnostics12112864Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma PatientGeorge Samonis0Aikaterini Bousmpoukea1Aristea Molfeta2Antonios D. Kalkinis3Kalliopi Petraki4Christos Koutserimpas5Dimitrios Bafaloukos6First Oncology Department, Metropolitan Hospital, Neon Faliron, 18547 Athens, GreeceFirst Oncology Department, Metropolitan Hospital, Neon Faliron, 18547 Athens, GreeceFirst Oncology Department, Metropolitan Hospital, Neon Faliron, 18547 Athens, GreeceDepartment of Nuclear Medicine, Metropolitan Hospital, Neon Faliron, 18547 Athens, GreeceDepartment of Pathology, Metropolitan Hospital, Neon Faliron, 18547 Athens, GreeceDepartment of Orthopaedics and Traumatology, “251” Hellenic Air Force General Hospital of Athens, 11525 Athens, GreeceFirst Oncology Department, Metropolitan Hospital, Neon Faliron, 18547 Athens, GreeceNivolumab, an anti-PD-1 check point inhibitor, is an immunotherapeutic agent, representing a major step in the treatment of melanoma. However, its use is associated with severe toxicities. Among them, gastrointestinal (GI) disorders from the lower GI tract have been widely reported. On the contrary, disorders from the upper GI tract are rare. Such a case of delayed nivolumab induced severe gastritis in a 53-year-old Caucasian female patient suffering metastatic melanoma is described. The patient’s symptoms from the upper GI tract began 4 months after nivolumab treatment initiation. The diagnosis was based on imaging, including PET/CT, endoscopical and pathological findings. The side effect was successfully treated with prolonged administration of proton pump inhibitors and corticosteroids. There are only a few cases of immune check point inhibitors (ICPis) induced upper GI tract disorders, while it seems that the symptoms from nivolumab induced upper GI tract damages appear later than those reported in the lower part. Nivolumab, among other side effects, may cause severe gastritis. Hence, this pathological entity should be included in the list of this drug’s side effects.https://www.mdpi.com/2075-4418/12/11/2864nivolumabgastritismelanomacorticosteroids |
| spellingShingle | George Samonis Aikaterini Bousmpoukea Aristea Molfeta Antonios D. Kalkinis Kalliopi Petraki Christos Koutserimpas Dimitrios Bafaloukos Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient Diagnostics nivolumab gastritis melanoma corticosteroids |
| title | Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient |
| title_full | Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient |
| title_fullStr | Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient |
| title_full_unstemmed | Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient |
| title_short | Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient |
| title_sort | severe gastritis due to nivolumab treatment of a metastatic melanoma patient |
| topic | nivolumab gastritis melanoma corticosteroids |
| url | https://www.mdpi.com/2075-4418/12/11/2864 |
| work_keys_str_mv | AT georgesamonis severegastritisduetonivolumabtreatmentofametastaticmelanomapatient AT aikaterinibousmpoukea severegastritisduetonivolumabtreatmentofametastaticmelanomapatient AT aristeamolfeta severegastritisduetonivolumabtreatmentofametastaticmelanomapatient AT antoniosdkalkinis severegastritisduetonivolumabtreatmentofametastaticmelanomapatient AT kalliopipetraki severegastritisduetonivolumabtreatmentofametastaticmelanomapatient AT christoskoutserimpas severegastritisduetonivolumabtreatmentofametastaticmelanomapatient AT dimitriosbafaloukos severegastritisduetonivolumabtreatmentofametastaticmelanomapatient |